Allspring Global Investments Holdings LLC Buys 76,728 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Allspring Global Investments Holdings LLC increased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 185.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 118,074 shares of the biopharmaceutical company’s stock after purchasing an additional 76,728 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.09% of Dynavax Technologies worth $1,651,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of DVAX. Charles Schwab Investment Management Inc. lifted its stake in shares of Dynavax Technologies by 9.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,081,789 shares of the biopharmaceutical company’s stock worth $15,978,000 after acquiring an additional 95,690 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Dynavax Technologies by 20.5% in the third quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock worth $20,083,000 after purchasing an additional 231,731 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Dynavax Technologies by 8.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,820 shares of the biopharmaceutical company’s stock worth $1,194,000 after purchasing an additional 6,339 shares during the period. Teacher Retirement System of Texas raised its position in Dynavax Technologies by 4.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 36,484 shares of the biopharmaceutical company’s stock valued at $539,000 after purchasing an additional 1,652 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Dynavax Technologies by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock worth $135,100,000 after buying an additional 270,730 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Insider Transactions at Dynavax Technologies

In other news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.98% of the company’s stock.

Dynavax Technologies Trading Up 0.3 %

NASDAQ DVAX opened at $11.84 on Tuesday. The firm has a market cap of $1.55 billion, a PE ratio of -197.30 and a beta of 1.26. Dynavax Technologies Co. has a 52 week low of $10.06 and a 52 week high of $15.15. The company has a quick ratio of 12.96, a current ratio of 13.81 and a debt-to-equity ratio of 0.41. The company has a 50 day moving average price of $12.31 and a 200 day moving average price of $13.26.

Analyst Ratings Changes

DVAX has been the topic of several research reports. The Goldman Sachs Group started coverage on Dynavax Technologies in a research note on Thursday, February 1st. They set a “neutral” rating and a $20.00 price target on the stock. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. Finally, William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.